Relmada Therapeutics (NASDAQ: RLMD) regains Nasdaq minimum bid compliance

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Relmada Therapeutics, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price requirement. The company received a written notice of compliance from Nasdaq’s Listing Qualifications Department stating that, for 10 consecutive trading days from August 29, 2025 to September 12, 2025, the closing bid price of its common stock was at or above $1.00 per share, satisfying Nasdaq Listing Rule 5550(a)(2).

Nasdaq informed Relmada that it now considers the listing compliance matter closed, meaning the company’s common stock remains listed on the Nasdaq Capital Market under the symbol RLMD. Relmada issued a press release on September 15, 2025 to communicate this development, which is referenced as an exhibit in the filing.

Positive

Nasdaq bid-price compliance regained: Relmada’s stock closed at or above $1.00 for 10 consecutive trading days, and Nasdaq confirmed the company is back in compliance with Listing Rule 5550(a)(2), closing the prior deficiency matter.

Negative

None.

Insights

Relmada has cleared Nasdaq’s minimum bid price hurdle, removing an immediate delisting risk.

Relmada Therapeutics received confirmation from Nasdaq that its common stock met the $1.00 minimum bid price for 10 consecutive trading days, from August 29 to September 12, 2025. This satisfies Nasdaq Listing Rule 5550(a)(2), which applies to companies on the Nasdaq Capital Market and focuses on maintaining a minimum share price.

With Nasdaq stating that it considers the matter closed, the near-term risk tied specifically to minimum bid price non-compliance is resolved. This preserves the company’s listing status and access to the Nasdaq market, which can be important for liquidity and institutional ownership. Future company disclosures may provide additional context on how Relmada manages ongoing compliance with Nasdaq standards.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

09/16/2025 - 08:06 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 15, 2025

RELMADA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada		001-39082		45-5401931
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2222 Ponce de Leon Blvd., Floor 3 Coral Gables, FL		33134
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (786) 629-1376

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of exchange on which registered
Common stock, $0.001 par value per share		RLMD		The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On September 16, 2025, Relmada Therapeutics, Inc. (the “Company”) issued a press release noting that on September 15, 2025, it had received written notice of compliance from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) stating that for 10 consecutive trading days, from August 29, 2025 to September 12, 2025, the closing bid price of the Company’s common stock has been at $1.00 per share or greater, and accordingly, the Company regained compliance with Nasdaq Listing Rule 5550(a)(2). Nasdaq informed the Company in the compliance notice that it now considered this matter closed. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release, dated September 15, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 16, 2025	RELMADA THERAPEUTICS, INC.

	By:	/s/ Sergio Traversa
	Name:	Sergio Traversa
	Title:	Chief Executive Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did Relmada Therapeutics (RLMD) announce regarding its Nasdaq listing?

Relmada Therapeutics announced that it received a written notice of compliance from Nasdaq confirming that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) related to the minimum bid price of its common stock.

How did Relmada Therapeutics regain compliance with Nasdaq’s minimum bid price rule?

Relmada regained compliance because, from August 29, 2025 to September 12, 2025, the closing bid price of its common stock was at or above $1.00 per share for 10 consecutive trading days, satisfying Nasdaq Listing Rule 5550(a)(2).

What does Nasdaq’s compliance notice mean for Relmada Therapeutics’ RLMD shares?

Nasdaq’s notice means that Relmada’s common stock remains in compliance with Nasdaq’s minimum bid price requirements, and Nasdaq has stated it now considers the prior bid-price deficiency matter closed.

What Nasdaq rule is Relmada Therapeutics now in compliance with?

Relmada is now in compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share for companies listed on the Nasdaq Capital Market.

Did Relmada Therapeutics issue a press release about regaining Nasdaq compliance?

Yes. Relmada issued a press release dated September 15, 2025 describing the receipt of Nasdaq’s written compliance notice; this press release is filed as Exhibit 99.1 to the report.

What is the trading symbol and market for Relmada Therapeutics stock?

Relmada Therapeutics’ common stock trades on the Nasdaq Capital Market under the symbol RLMD.